Maria Majdan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4476247/publications.pdf

Version: 2024-02-01

		394421	243625
112	2,239	19	44
papers	citations	h-index	g-index
121	121	121	3235
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Research and Therapy, 2008, 10, R30.	3.5	387
2	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine, the, 2020, 8, 963-974.	10.7	348
3	Remission and rheumatoid arthritis: Data on patients receiving usual care in twentyâ€four countries. Arthritis and Rheumatism, 2008, 58, 2642-2651.	6.7	156
4	Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care and Research, 2012, 64, 206-214.	3.4	144
5	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	5.6	82
6	Leptin serum levels in rheumatoid arthritis patients: relation to disease duration and activity. Rheumatology International, 2008, 28, 585-591.	3.0	77
7	Serum Amyloid A as a Marker of Persistent Inflammation and an Indicator of Cardiovascular and Renal Involvement in Patients with Rheumatoid Arthritis. Mediators of Inflammation, 2014, 2014, 1-7.	3.0	75
8	Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrology Dialysis Transplantation, 2004, 19, 917-924.	0.7	66
9	Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. Annals of the Rheumatic Diseases, 2012, 71, 1942-1949.	0.9	59
10	Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis. Rheumatology International, 2010, 30, 731-737.	3.0	54
11	Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro. Rheumatology International, 2006, 26, 422-426.	3.0	39
12	The Relationship between Hematological Markers of Systemic Inflammation (Neutrophil-To-Lymphocyte, Platelet-To-Lymphocyte, Lymphocyte-To-Monocyte Ratios) and Ultrasound Disease Activity Parameters in Patients with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 2760.	2.4	31
13	Factors associated with quality of life in systemic sclerosis: a cross-sectional study. Quality of Life Research, 2019, 28, 3347-3354.	3.1	29
14	Epigenetic aspects of rheumatoid arthritis: contribution of non-coding RNAs. Seminars in Arthritis and Rheumatism, 2017, 46, 724-731.	3.4	28
15	Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacological Reports, 2007, 59, 233-7.	3.3	27
16	Radiation synovectomy with 90Y colloid in the therapy of recurrent knee joint effusions in patients with inflammatory joint diseases. Rheumatology International, 2007, 27, 729-734.	3.0	26
17	The Relationship Between Carotid Intima-Media Thickness and the Activity of Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2011, 17, 249-255.	0.9	25
18	Coexistence of five autoimmune diseases: diagnostic and therapeutic difficulties. Rheumatology International, 2008, 28, 919-923.	3.0	22

#	Article	IF	CITATIONS
19	Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity. Rheumatology International, 2018, 38, 1207-1215.	3.0	22
20	Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. Reumatologia, 2018, 56, 203-211.	1.1	21
21	Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis. Clinical Rheumatology, 2009, 28, 955-959.	2.2	18
22	Serological profile of patients with systemic sclerosis. Postepy Higieny I Medycyny Doswiadczalnej, 2014, 68, 987-991.	0.1	17
23	Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro. European Journal of Pharmacology, 2006, 535, 95-97.	3.5	16
24	Kynurenic Acid in Synovial Fluid and Serum of Patients with Rheumatoid Arthritis, Spondyloarthropathy, and Osteoarthritis. Journal of Rheumatology, 2013, 40, 903-909.	2.0	15
25	Induction of response with etanercept–methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clinical Rheumatology, 2013, 32, 1275-1281.	2.2	15
26	Relationship between rheumatoid arthritis activity and antithyroid antibodies. Polish Archives of Internal Medicine, 2013, 123, 394-400.	0.4	15
27	Parthenolide Inhibits Proliferation of Fibroblast-Like Synoviocytes In Vitro. Inflammation, 2008, 31, 281-285.	3.8	14
28	The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2198986.	2.7	14
29	Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-α agents. Archives of Medical Science, 2013, 1, 112-117.	0.9	13
30	Gender Differences in Cardiovascular Risk Profile in Rheumatoid Arthritis Patients with Low Disease Activity. BioMed Research International, 2019, 2019, 1-7.	1.9	13
31	Diastolic dysfunction in rheumatoid arthritis patients with low disease activity. Clinical Rheumatology, 2019, 38, 1131-1137.	2.2	13
32	Treatment and its side effects in ANCA-associated vasculitides – Study based on POLVAS registry data. Advances in Medical Sciences, 2020, 65, 156-162.	2.1	13
33	\hat{l}^2 2-microglobulin as a marker of systemic lupus erythematosus activity. Advances in Clinical and Experimental Medicine, 2018, 27, 379-382.	1.4	13
34	Biological impact of iberdomide in patients with active systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 1136-1142.	0.9	13
35	Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis. Cardiovascular Ultrasound, 2018, 16, 18.	1.6	12
36	Overlap syndromes in systemic sclerosis. Postepy Dermatologii I Alergologii, 2018, 35, 246-250.	0.9	12

#	Article	IF	Citations
37	Hypermethylation of the miR-155 gene in the whole blood and decreased plasma level of miR-155 in rheumatoid arthritis. PLoS ONE, 2020, 15, e0233897.	2.5	12
38	Genetic Determination of TNF and Myeloperoxidase Production in Dialyzed Patients with Diabetic Nephropathy. Renal Failure, 2004, 26, 633-639.	2.1	11
39	Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis. Clinical Rheumatology, 2011, 30, 61-69.	2.2	11
40	Systemic Inflammatory Parameters in Patients with Elderly-Onset Rheumatoid Arthritis (EORA) and Young-Onset Rheumatoid Arthritis (YORA)â€"An Observational Study. Journal of Clinical Medicine, 2021, 10, 1204.	2.4	11
41	Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis. Polish Archives of Internal Medicine, 2017, 127, 815-822.	0.4	11
42	Kynurenic acid content in anti-rheumatic herbs. Annals of Agricultural and Environmental Medicine, 2013, 20, 800-2.	1.0	11
43	Differential approach to peripheral blood cell ratios in patients with systemic lupus erythematosus and various manifestations. Rheumatology International, 2020, 40, 1625-1629.	3.0	10
44	Peptidyl Arginine Deiminase Type 4 Gene Promoter Hypo-Methylation in Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 2049.	2.4	10
45	Polymorphisms of Tumor Necrosis Factor and Myeloperoxidase Genes in Patients with Chronic Renal Failure on Peritoneal Dialysis. Molecular Diagnosis and Therapy, 2003, 7, 175-180.	1.1	9
46	Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients. Pharmacological Reports, 2010, 62, 719-725.	3.3	9
47	Comparison of clinical and serological parameters in female and male patients with systemic sclerosis. Reumatologia, 2016, 53, 315-320.	1.1	9
48	Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia, 2017, 55, 290-297.	1,1	9
49	Nephrotic syndrome as a clinical manifestation of systemic sclerosis. Rheumatology International, 2007, 27, 1087-1089.	3.0	8
50	Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe. Journal of Dermatological Treatment, 2018, 29, 8-12.	2.2	8
51	Assessment of education requirements for patients with rheumatoid arthritis, based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT), in the light of some health problems – A cross-sectional study. Annals of Agricultural and Environmental Medicine, 2016, 23, 361-367.	1.0	8
52	Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations. Advances in Clinical and Experimental Medicine, 2018, 27, 1253-1257.	1.4	8
53	Efficacy of radiosynoviorthesis and its impact on chosen inflammatory markers. Rheumatology International, 2012, 32, 2339-2344.	3.0	7
54	Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study. Reumatologia, 2018, 56, 140-148.	1.1	7

#	Article	IF	CITATIONS
55	Antiphospholipid antibodies during 6-month treatment with infliximab: A preliminary report. Medical Science Monitor, 2014, 20, 1227-1231.	1.1	7
56	Clinical picture of late-onset systemic lupus erythematosus in a group of Polish patients. Polish Archives of Internal Medicine, 2015, 125, 538-544.	0.4	7
57	Presence of organ‑specific antibodies in patients with systemic sclerosis. Polish Archives of Internal Medicine, 2016, 126, 862-869.	0.4	7
58	Haematological abnormalities in systemic sclerosis. Reumatologia, 2020, 58, 162-166.	1.1	6
59	Clinical consequences of the presence of anti-RNA Pol III antibodies in systemic sclerosis. Postepy Dermatologii I Alergologii, 2020, 37, 909-914.	0.9	6
60	The prevalence and significance of anti-PM/Scl antibodies in systemic sclerosis. Annals of Agricultural and Environmental Medicine, 2021, 28, 189-192.	1.0	6
61	Prevalence of selected organ-specific autoantibodies in rheumatoid arthritis and primary Sjögren's syndrome patients. Reumatologia, 2015, 53, 61-68.	1.1	5
62	Kidney involvement in antiphospholipid syndrome – current diagnostic and management problems. Reumatologia, 2017, 55, 213-214.	1.1	5
63	IRF5 promoter methylation as a new potential marker of rheumatoid arthritis. Polish Archives of Internal Medicine, 2019, 129, 370-376.	0.4	5
64	Subphenotypes of ANCA-associated vasculitis identified by latent class analysis. Clinical and Experimental Rheumatology, 2021, 39, 62-68.	0.8	4
65	Reasons for diagnostic delays of axial spondyloarthritis. WiadomoÅci Lekarskie, 2019, 72, 1607-1610.	0.3	3
66	Antibodies against cyclic citrullinated peptide don't decrease after 6Âmonths of infliximab treatment in refractory rheumatoid arthritis. Rheumatology International, 2011, 31, 1439-1443.	3.0	2
67	Letter to the Editor Ziarniniakowatość z zapaleniem naczyń – nowa nazwa ziarniniakowatości Wegenera i potrzeba jej upowszechnienia. Reumatologia, 2012, 6, 541-542.	1.1	2
68	Adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in therapeutic programmes $\hat{a} \in \text{``personal experience}$. Reumatologia, 2013, 1, 9-14.	1.1	2
69	Characteristics of Polish patients with systemic lupus erythematosus obtained from SESAME registry. Activity of the disease, degree of impairment, and availability of social care. Reumatologia, 2013, 5, 332-341.	1.1	2
70	Recommendations for diagnosis and treatment Selected principles of proper education of women with rheumatic diseases in respect of pregnancy planning. Reumatologia, 2014, 1, 49-56.	1.1	2
71	Fertility, pregnancy planning, and pharmacotherapy during the pregnancy, postpartum and breastfeeding period in patients with rheumatoid arthritis and other inflammatory arthropathies. Reumatologia, 2014, 52, 7-21.	1.1	2
72	Coexistence of diabetes mellitus type 1 with diffuse systemic sclerosis – case report and literature review. Reumatologia, 2017, 2, 104-107.	1.1	2

#	Article	IF	Citations
73	Urticarial rash, fever, and arthritis: A case of refractory Adultâ€onset Still's disease with good response to tocilizumab. Dermatologic Therapy, 2019, 32, e13041.	1.7	2
74	Nephrotic syndrome in the course of type 1 diabetes mellitus and systemic lupus erythematosus with secondary antiphospholipid syndrome $\hat{a} \in \hat{a}$ diagnostic and therapeutic problems. A \hat{A} case-based review. Reumatologia, 2020, 58, 331-334.	1.1	2
75	ANCA-associated vasculitis patients treated in Polish intensive care units – retrospective characteristics based on the POLVAS registry. Anaesthesiology Intensive Therapy, 2020, 52, 281-286.	1.0	2
76	CLINICAL AND SEROLOGICAL PARAMETERS OF PROGRESSION AND PROGNOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS – A STATE OF THE ART REVIEW. WiadomoÅci Lekarskie, 2020, 73, 1528-1532.	0.3	2
77	The occurrence of antibodies against Legionella pneumophila in patients with autoimmune rheumatic diseases. Polish Archives of Internal Medicine, 2015, 125, 749-754.	0.4	2
78	The presence of particular criteria and non-criteria antiphospholipid antibodies in patients with uterine malignancies. Polish Archives of Internal Medicine, 2020, 130, 1037-1042.	0.4	2
79	Editorial paper Gout – new diagnostic and therapeutic options. Reumatologia, 2013, 1, 1-8.	1.1	1
80	Remission in lupus nephritis – report of three cases. Reumatologia, 2013, 1, 85-88.	1.1	1
81	Recommendations for diagnosis and treatment Chronic inflammation of the joints – the transition from pediatric rheumatologist to adult rheumatologist. Recommendations of the Panel of Experts on National Consultant in the field of rheumatology (recommendations in the context of the conditions) Tj ETQq1 ∑	1 0. 7 84314	4 r <mark>\$</mark> BT /Overl
82	Effectiveness and safety of the use of rituximab in patients with active rheumatoid rthritis – 5 years' personal observations. Reumatologia, 2013, 1, 20-25.	1.1	1
83	Pregnancy in patients with systemic lupus erythematosus Reumatologia, 2013, 1, 77-79.	1.1	1
84	Review Carbohydrate metabolism disorders in patients with rheumatoid arthritis and ankylosing spondylitis $\hat{a} \in \text{``impact}$ of the severity of the inflammatory process and disease activity. Reumatologia, 2014, 1, 62-68.	1.1	1
85	Certolizumab pegol – new option in the treatment of psoriatic arthritis. Reumatologia, 2014, 3, 181-188.	1.1	1
86	Influence of antiphospholipid antibody positivity on glomerular filtration rate markers in a group of systemic sclerosis patients – a 24-month observation. Central-European Journal of Immunology, 2017, 2, 161-166.	1.2	1
87	LATE-ONSET SJ×GREN'S SYNDROM. Wiadomości Lekarskie, 2019, 72, 1687-1690.	0.3	1
88	Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population. Advances in Clinical and Experimental Medicine, 2018, 27, 493-499.	1.4	1
89	Clinical and serological parameters of progression and prognosis in patients with systemic sclerosis - a state of the art review. WiadomoÅci Lekarskie, 2020, 73, 1528-1532.	0.3	1
90	Subphenotypes of ANCA-associated vasculitis identified by latent class analysis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 62-68.	0.8	1

#	Article	IF	CITATIONS
91	The relationship of ADAMTSL2 and LRPAP1 gene methylation level with rheumatoid arthritis activity. Clinical and Experimental Rheumatology, 0, , .	0.8	1
92	Respiratory involvement in antineutrophil cytoplasmic antibody-associated vasculitides: a retrospective study based on POLVAS registry. Clinical and Experimental Rheumatology, 2022, , .	0.8	1
93	Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland. Medical Science Monitor, 0, 28, .	1.1	1
94	Catastrophic antiphospholipid syndrome in a patient with systemic lupus erythematosus. Reumatologia, 2013, 1, 73-76.	1.1	0
95	Etanercept in a therapeutic program for the treatment of rheumatoid arthritis and ankylosing spondylitis – 7 years' personal experience. Reumatologia, 2013, 1, 15-19.	1.1	0
96	Selected problems of biologic therapy in rheumatoid arthritis patients – pregnancy during therapy Reumatologia, 2013, 1, 93-95.	1.1	0
97	Rheumatic manifestations in hepatitis C virus infection Reumatologia, 2013, 1, 96-99.	1.1	0
98	Selected problems of biologic therapy in rheumatoid arthritis patients – inefficacy of several biologic therapies Reumatologia, 2013, 1, 89-92.	1.1	0
99	Central nervous system lupus – three different manifestations of the disease. Reumatologia, 2013, 1, 80-84.	1.1	0
100	Recommendations for diagnosis and treatment Recommendations for obstetric management and principles of cooperation between rheumatologists and obstetricians in systemic connective tissue disease patients. Reumatologia, 2014, 1, 38-48.	1.1	0
101	Recommendations for diagnosis and treatment Fertility, pregnancy planning, and treatment during the pregnancy, postpartum and breastfeeding period in patients with antiphospholipid syndrome. Reumatologia, 2014, 1, 30-37.	1.1	0
102	Carbohydrate metabolism disorders in patients with rheumatoid arthritis and ankylosing spondylitis – impact of treatment. Reumatologia, 2014, 2, 129-135.	1.1	0
103	Recommendations for diagnosis and treatment Fertility, pregnancy and breastfeeding in systemic lupus erythematosus patients. Reumatologia, 2014, 1, 22-29.	1.1	0
104	Response to: Comment on "Serum Amyloid A as a Marker of Persistent Inflammation and an Indicator of Cardiovascular and Renal Involvement in Patients with Rheumatoid Arthritis― Mediators of Inflammation, 2015, 2015, 1-1.	3.0	0
105	Methylation Pattern of the SOCS3 and IL6R Promoters in Rheumatoid Arthritis. International Journal of Inflammation, 2020, 2020, 1-7.	1.5	0
106	Sicca syndrome in the same family – the importance of anti-Ro60, anti-Ro52 and anti-La antibody profiling in Sjögren's syndrome. Reumatologia, 2021, 59, 260-264.	1.1	0
107	The present and future status of internal medicine in Poland and in the world. Polish Archives of Internal Medicine, 2016, 126, 939-941.	0.4	0
108	Glucose tolerance disorders during treatment with glucocorticoids in patients with inflammatory diseases of the musculoskeletal system $\hat{a} \in \hat{b}$ based on the analysis of data from the literature and own research results. Postepy Higieny I Medycyny Doswiadczalnej, 2017, 71, 0-0.	0.1	0

#	Article	IF	CITATIONS
109	Epigenetic determinants in rheumatoid arthritis: the influence of DNA methylation and histone modifications. Postepy Higieny I Medycyny Doswiadczalnej, 2017, 71, 0-0.	0.1	0
110	ZespóÅ, hemofagocytowy indukowany terapiÄ hormonalnÄ â€" studium przypadku klinicznego. Acta Haematologica Polonica, 2018, 49, 151-156.	0.3	0
111	Plasma micro-RNA-22 is associated with disease activity in well-established rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.8	O
112	The relationship of ADAMTSL2 and LRPAP1 gene methylation level with rheumatoid arthritis activity Clinical and Experimental Rheumatology, 2021, , .	0.8	0